Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.71 |
| ▸ | GSK3B | P49841 | 10/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953449 | 0.94 | CDK2 (0.81) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13122666 | 0.94 | CDK2 (0.68) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953676 | 0.91 | GSK3B (0.82) | CDK2GSK3BCCNE1 | |
| SCHEMBL13121881 | 0.91 | CDK2 (0.62) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13121822 | 0.89 | CDK2 (0.60) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13120242 | 0.89 | CDK2 (0.62) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL14418893 | 0.87 | CDK2 (0.54) | CDK2GSK3BCCNA2CCNA1MEN1 | |
| SCHEMBL13305640 | 0.87 | CDK2 (0.54) | CDK2GSK3BMEN1KMT2A | |
| SCHEMBL12953603 | 0.87 | CDK2 (0.70) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL12953835 | 0.87 | GSK3B (0.73) | CDK2GSK3BCCNE1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |